January 5, 2016

OICR funds world-first clinical trial using cancer-fighting viruses

Oncology Viruses - Image of a cell.

Drs. John Bell, David Stojdl and Brian Lichty have together been investigating viral therapies for over 15 years. On July 10 in Ottawa they announced that this work has now moved to the clinic, with the launch of a world-first clinical trial using their custom-made cancer-fighting viruses.

Dr. Bell is leader of OICR’s Immuno- and Bio-therapies Program (ORBiT), based at the Ottawa Hospital Research Institute.

Continue reading – OICR funds world-first clinical trial using cancer-fighting viruses

November 9, 2015

FACIT start-up company Turnstone Biologics secures $11.3 million in financing, boosts leadership

turnstoneTurnstone Biologics Inc., a FACIT-incubated company spun out of research conducted in OICR’s ORBiT Program, has secured $11.3 million in new financing. This investment in the company has allowed it to take another step forward in its development with the hiring of Dr. Sammy J. Farah as Chief Executive Officer and Dr. Brian D. Lichty as Chief Technology Officer (CTO). Farah is a veteran vaccine executive with extensive technology and product development expertise. Lichty, a distinguished scientist, is a leader in the development of oncolytic viral therapies and one of Turnstone’s founding scientists. The financing round was led by Versant Ventures and more than $20 million in follow-on capital has been committed.

“We are very pleased to have concluded this financing with an experienced venture capital firm of Versant’s calibre, and to be able to enhance the Company’s leadership with compelling management,” said Jeff Courtney, Chief Commercial Officer of FACIT, which is Turnstone’s founding investor.

Continue reading – FACIT start-up company Turnstone Biologics secures $11.3 million in financing, boosts leadership